目的 探討厄貝沙坦聯(lián)合貝那普利治療慢性腎臟病的臨床效果。方法 選取2019年8月—2020年7月和平縣人民醫(yī)院收治的76例慢性腎臟病患者，隨機(jī)分為對(duì)照組和治療組，每組各38例。對(duì)照組口服鹽酸貝那普利片10～20 mg/次，1次/d。治療組在對(duì)照組治療基礎(chǔ)上口服厄貝沙坦片75～150 mg/次，1次/d。兩組患者連續(xù)治療6個(gè)月。觀察兩組的臨床療效，比較兩組血壓、血肌酐、尿素氮、血漿白蛋白、24小時(shí)尿蛋白定量的變化情況。結(jié)果 治療后，治療組總有效率94.74%，顯著高于對(duì)照組的78.95%（P<0.05）。治療后，兩組收縮壓、舒張壓、血肌酐、血尿素氮均較治療前顯著降低，但血漿白蛋白水平顯著升高（P<0.05）；治療后，治療組血壓和腎功能指標(biāo)改善優(yōu)于對(duì)照組（P<0.05）。兩組治療1、3、6個(gè)月24 h尿蛋白定量均較同組治療前顯著降低（P<0.05）；且治療組24 h尿蛋白定量顯著低于對(duì)照組治療同期（P<0.05）。結(jié)論 厄貝沙坦聯(lián)合貝那普利治療慢性腎臟病具有較好的臨床療效，有利于減少蛋白尿，保護(hù)腎功能，延緩腎功能惡化，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of irbesartan combined with benazepril in treatment of chronic kidney disease. Methods A total of 76 patients with chronic kidney disease admitted to Heping County People's Hospital from August 2019 to July 2020 were randomly divided into control group and treatment group, with 38 patients in each group. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 — 20 mg/time, once daily. Patients in the treatment group were po administered with Irbesartan Tablets on the basis of the control group, 75—150 mg/time, once daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, the changes of blood pressure, serum creatinine, urea nitrogen, plasma albumin and 24 h urinary protein were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 94.74%, which was significantly higher than that of the control group (78.95%, P<0.05). After treatment, systolic blood pressure, diastolic blood pressure, serum creatinine, and blood urea nitrogen in both groups were significantly decreased, but plasma albumin level was significantly increased (P<0.05). After treatment, the improvement of blood pressure and renal function in the treatment group was better than that in the control group (P<0.05). 24 h Urinary protein level in two groups at 1, 3, and 6 months was significantly lower than that before treatment (P<0.05). The 24 h urinary protein level in the treatment group was significantly lower than that in the control group at the same time of the treatment (P<0.05). Conclusion Irbesartan combined with benazepril has a good clinical effect in treatment of chronic kidney disease, and can reduce proteinuria, protect renal function,delay the deterioration of renal function, which has a certain clinical application value.

R983

河源市科技計(jì)劃項(xiàng)目（河科2019032）